These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31524233)

  • 1. Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells.
    Liu B; Liu ZZ; Zhou ML; Lin JW; Chen XM; Li Z; Gao WB; Yu ZD; Liu T
    Mol Med Rep; 2019 Sep; 20(3):2823-2831. PubMed ID: 31524233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells.
    Chiawpanit C; Wathikthinnakorn M; Sawasdee N; Phanthaphol N; Sujjitjoon J; Junking M; Yamabhai M; Panaampon J; Yenchitsomanus PT; Panya A
    Int Immunopharmacol; 2024 Jul; 136():112273. PubMed ID: 38810311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
    Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
    Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
    Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
    Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
    Kang CH; Kim Y; Lee SM; Choi SU; Park CH
    Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
    Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
    J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4.
    Jamali A; Hadjati J; Madjd Z; Mirzaei HR; Thalheimer FB; Agarwal S; Bonig H; Ullrich E; Hartmann J
    Front Immunol; 2020; 11():2028. PubMed ID: 32983147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
    Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
    Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A TCR-based Chimeric Antigen Receptor.
    Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
    Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
    Huo Q; Lv J; Zhang J; Huang H; Hu H; Zhao Y; Zhang X; Wang Y; Zhou Y; Qiu J; Ye Y; Huang A; Chen Y; Qin L; Qin D; Li P; Cai G
    Cytotherapy; 2023 Oct; 25(10):1037-1047. PubMed ID: 37436338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.